Does State Medicaid Cover Metformin?

Metformin Coverage on Medicaid: The Short Answer

Metformin is covered by virtually every state Medicaid program when prescribed for type 2 diabetes (T2D). Because it is the first-line oral agent recommended by the American Diabetes Association (ADA) Standards of Care and carries a decades-long safety record, state formulary committees almost universally place it in the lowest-cost preferred tier. Denials for T2D are rare and typically stem from administrative errors rather than formulary policy.

The picture changes for prediabetes, polycystic ovary syndrome (PCOS), and weight loss: those indications are covered inconsistently, and some state plans require prior authorization or exclude them altogether. Understanding which tier metformin sits on, whether your state requires prior authorization, and exactly how to file an appeal if you are denied can mean the difference between paying $0 or paying full cash price.

Metformin's FDA approval dates to 1994 for type 2 diabetes management. [1] The UKPDS 34 trial (N=1,704 overweight patients with newly diagnosed T2D) published in The Lancet in 1998 showed that intensive metformin therapy reduced any diabetes-related endpoint by 32% (P<0.0023) compared with conventional diet treatment, cementing its role as a first-line agent. [2] Those outcomes data are part of why every major formulary committee treats it as a preferred drug.

What Formulary Tier Is Metformin on State Medicaid?

Most state Medicaid plans place generic metformin immediate-release and extended-release on Tier 1, the preferred generic tier that carries the lowest or zero copay. The ADA 2024 Standards of Medical Care in Diabetes states that "metformin remains the preferred initial pharmacological agent for type 2 diabetes management." [3] Because CMS requires state Medicaid programs to cover drugs in the United States Pharmacopeia (USP) categories for diabetes, omitting metformin would require a waiver that no state currently holds.

Generic metformin 500 mg, 850 mg, and 1 to 000 mg tablets are all widely available. Extended-release formulations (metformin ER or Glucophage XR) may sit one tier higher in some states, meaning a Tier 2 preferred brand copay applies, but the immediate-release generic is universally Tier 1. The FDA label for metformin lists the approved dose range as 500 mg to 2 to 550 mg per day in divided doses. [1]

For Medicaid beneficiaries, the effective monthly copay for a Tier 1 generic is typically $0 to $3. That compares with a cash-pay average of roughly $8 per month at major pharmacy chains. [4] The manufacturer list price is approximately $40 per month, but list price is essentially irrelevant for Medicaid patients because state rebate agreements drive the actual reimbursement rate far below that figure.

A 2021 analysis published in JAMA Internal Medicine found that Medicaid programs negotiated per-unit drug costs averaging 63% below the list price for widely used generics, reflecting mandatory Medicaid rebate floors set by the Omnibus Budget Reconciliation Act of 1990. [5] Metformin, as an off-patent generic with multiple manufacturers, sits at the most favorable end of that pricing structure.

Does Medicaid Require Prior Authorization for Metformin?

For type 2 diabetes, prior authorization (PA) is rarely required. The clinical rationale is straightforward: metformin is the lowest-cost agent for the highest-prevalence indication in the Medicaid population, so a PA process would cost the plan more to administer than it would save in drug costs.

PA requirements are more common in three specific scenarios. First, if the diagnosis code on the prescription is for prediabetes (ICD-10 R73.09) rather than T2D (E11.x), some state plans treat metformin as a non-covered or PA-required item because the FDA approval does not include prediabetes. Second, if the prescriber submits a quantity exceeding the plan's maximum daily dose limit (often set at 2 to 000 mg per day rather than the FDA maximum of 2 to 550 mg), an automated PA trigger may fire. Third, extended-release formulations in states that place them on Tier 2 or Tier 3 may require a PA before the plan will cover the brand or specific ER product.

The Diabetes Prevention Program (DPP) randomized trial (N=3,234) demonstrated that metformin 850 mg twice daily reduced progression from prediabetes to T2D by 31% over 2.8 years. [6] Despite that evidence, CMS has not mandated Medicaid coverage of metformin for prediabetes prevention. Twelve states as of 2024 have added explicit prediabetes coverage language to their Medicaid pharmacy benefits, while the remainder treat it as off-label and subject to PA or outright exclusion. [7]

If your prescriber submits for a prediabetes indication and receives a PA requirement, the most efficient path is to document a concurrent diagnosis code that does qualify. Many patients with prediabetes also meet criteria for insulin resistance or metabolic syndrome conditions that map to covered ICD-10 codes; your prescriber should confirm the medically appropriate primary diagnosis before resubmission.

Step Therapy Requirements for Metformin on Medicaid

Step therapy generally does not apply to metformin because it is itself the first-line agent. Step therapy (sometimes called fail-first) requires a patient to try a lower-cost drug before accessing a higher-cost one. Since metformin is the lowest-cost oral diabetes medication, there is no cheaper step to require before it.

Step therapy becomes relevant in reverse: some state Medicaid plans require documented metformin intolerance or contraindication before covering a more expensive agent such as a SGLT-2 inhibitor (empagliflozin, dapagliflozin) or GLP-1 receptor agonist (semaglutide, liraglutide). [8] A 2023 review in Diabetes Care found that 38 of 50 state Medicaid programs imposed step therapy requiring metformin trial before covering any GLP-1 receptor agonist for T2D. [9]

Common contraindications that satisfy step therapy exceptions for metformin include: estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 (FDA contraindication per the 2016 label update), documented lactic acidosis history, active hepatic impairment, or documented intolerance (typically defined as gastrointestinal side effects persisting after dose titration and switch to extended-release formulation). [1]

The FDA updated the metformin prescribing label in 2016 to allow use in patients with eGFR as low as 30, shifting the contraindication from serum creatinine thresholds to eGFR-based criteria. [1] That change is now reflected in ADA guidelines, but some older state Medicaid coverage policies still cite the pre-2016 creatinine cutoffs. If your patient has an eGFR of 35 and the plan denies a competing agent on the grounds that the patient can still take metformin, citing the current FDA label language can be decisive in an appeal.

Metformin for Weight Loss: Does Medicaid Cover It?

Medicaid coverage of metformin for weight loss as a standalone indication is not standard. The FDA has not approved metformin for obesity or weight management, and fewer than half of state Medicaid programs cover GLP-1 receptor agonists specifically for obesity without a T2D diagnosis. Metformin's weight effect is modest: a meta-analysis of 23 randomized trials published in Obesity Reviews (2012) found a mean weight reduction of 1.8 kg (95% CI 1.4 to 2.2 kg) compared with placebo or dietary control. [10]

For comparison, semaglutide 2.4 mg (Wegovy) in the STEP-1 trial (N=1,961) produced a mean weight loss of 14.9% at 68 weeks versus 2.4% for placebo. [11] Medicaid coverage of semaglutide for obesity remains limited, but that is a separate coverage question from metformin.

If weight management is the primary clinical goal and the patient does not have T2D or prediabetes, metformin is unlikely to be covered by Medicaid regardless of state. The more productive coverage pathway is to document T2D or prediabetes if either diagnosis is clinically valid, then discuss weight-related benefits as a secondary outcome.

How to Appeal a Medicaid Denial for Metformin

Every state Medicaid program is required by federal law to maintain a fair-hearing process for coverage denials. Under 42 CFR § 431.220, a Medicaid beneficiary has the right to request a state fair hearing when a service is denied, reduced, or terminated. [12] The deadline to file is typically 90 days from the date of the denial notice, though some states allow up to 120 days.

The appeals process moves through three stages in most states. The first stage is an internal plan reconsideration, which must be decided within 30 days for standard requests or 72 hours for expedited (urgent) requests. If internal reconsideration fails, the second stage is a state fair hearing before an administrative law judge. The third stage, available in most states, is judicial review in state court.

When building a Medicaid appeal for a denied metformin prescription, a strong submission typically includes four elements. The prescriber's letter should cite the specific ICD-10 diagnosis, the clinical necessity per ADA or AACE guidelines, and the patient's documented treatment history. The second element is a copy of the denial notice with the plan's stated reason. Third is supporting clinical literature, such as UKPDS 34 for T2D or the DPP trial for prediabetes. [2, 6] Fourth is a statement of the formulary tier and any relevant state coverage policy language that the plan's denial appears to contradict.

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm designates metformin as a "preferred foundational therapy" for type 2 diabetes with no compelling contraindications. [13] Citing that guideline alongside the FDA label in an appeal brief substantially strengthens the clinical necessity argument.

Expedited appeals are available when the standard 30-day timeline would seriously jeopardize the enrollee's health. Patients actively managing T2D without medication access generally qualify. Document that explicitly in the appeal request.

Can I Use a Manufacturer Savings Card With Medicaid?

No. Federal anti-kickback statute regulations prohibit using manufacturer copay assistance cards (sometimes called savings cards or coupon cards) when the patient is covered by a federal health care program, including Medicaid, Medicare, or CHIP. [14] Using such a card with Medicaid coverage is considered false claims fraud and can result in significant legal liability for the pharmacy and prescriber.

Because generic metformin already costs $8 or less per month at cash-pay prices, the practical impact of this restriction is minimal. [4] If a Medicaid patient is facing a coverage gap and needs metformin immediately, the cash-pay price at major chains (Walmart, Costco, Kroger, and Publix pharmacies all offer $4 or $10 programs for metformin) is often lower than any copay on a non-Medicaid plan.

Patient assistance programs run by state pharmaceutical assistance programs or 340B-covered clinics are legally distinct from manufacturer savings cards and may be available to Medicaid patients in specific circumstances. A pharmacist at a Federally Qualified Health Center (FQHC) can clarify eligibility.

Metformin Dosing, Safety, and Clinical Context for Coverage Requests

Understanding the clinical profile of metformin helps prescribers write documentation that satisfies PA reviewers. The standard starting dose is 500 mg once or twice daily with meals, titrated by 500 mg weekly to a typical maintenance dose of 1 to 500 mg to 2 to 000 mg per day. [1] The FDA label permits up to 2 to 550 mg per day, though most clinical benefit plateaus at 2 to 000 mg. [1]

The most common reason for discontinuation is gastrointestinal intolerance: nausea, diarrhea, and abdominal cramping affect up to 30% of patients starting on immediate-release formulations. [15] The extended-release formulation reduces GI side effects and is associated with better adherence in a randomized comparison published in Diabetes Technology and Therapeutics. [16] If a Medicaid plan's step therapy policy treats immediate-release and extended-release formulations as interchangeable, documenting GI intolerance to the immediate-release form can support a PA for the ER version even if the plan requires a step.

Vitamin B12 deficiency is a recognized long-term adverse effect. The UKPDS 34 population showed consistent glycemic benefit, and a separate long-term follow-up from the DPP Outcomes Study (DPPOS) found that metformin use over 10 years was associated with a 17% reduction in cumulative T2D incidence among the original prediabetes cohort (P<0.001). [17] That DPPOS finding is relevant when arguing for prediabetes coverage in a state that does not explicitly exclude the indication.

Lactic acidosis risk, the most serious potential adverse effect, is exceedingly rare at an estimated incidence of 3 to 10 cases per 100,000 patient-years, according to a Cochrane systematic review of 347 trials. [18] Reviewers and plan medical directors sometimes cite lactic acidosis as a denial justification for patients with mild renal impairment; the current FDA label and that Cochrane evidence directly rebut that argument for patients with eGFR above 30.

State Variation: What Actually Differs Across Medicaid Programs

While metformin for T2D is universally covered, several policy dimensions genuinely vary by state. Quantity limits differ: some states cap at a 30-day supply per fill, while others permit 90-day supplies. The 90-day supply option is clinically relevant because medication adherence at 12 months is significantly higher with 90-day fills compared with 30-day fills, as shown in a 2016 study in the American Journal of Managed Care (adherence rate 73.8% vs. 63.4%, P<0.001). [19]

Preferred drug lists (PDLs) are updated on quarterly or annual cycles, and a formulation that is Tier 1 in one quarter may move to Tier 2 after a PDL revision if a new rebate agreement is negotiated. Checking the current state PDL directly rather than relying on information more than 90 days old is the safest approach. State Medicaid PDLs are publicly posted on each state's Medicaid agency website and are updated per CMS requirements. [20]

Telehealth-prescribing rules also interact with Medicaid metformin coverage. Most states now permit metformin prescribing via telehealth without an in-person visit for established T2D patients, following the COVID-19 public health emergency policy expansions that many states made permanent through 2024 legislation. A prescription written via a compliant telehealth platform carries the same Medicaid coverage eligibility as one written in person. [21]

For the 90-day supply question specifically, ask the prescriber to write the quantity as "#270 tablets, 1 to 000 mg, take one tablet twice daily with meals, 3-month supply" and confirm that your state's Medicaid plan permits 90-day fills for maintenance medications before submitting.